Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
65
Views
7
CrossRef citations to date
0
Altmetric
Short Report

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

Wenbo Shao1 Department of Surgical Oncology (Interventional Therapy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
,
Caixia Li2 Department of Interventional Radiology, Qilu Hospital of Shandong University, Jinan, People’s Republic of China
,
Jun Tang3 Department of Interventional Radiology, Shandong Medical Imaging Research Institute, Jinan, People’s Republic of ChinaCorrespondence[email protected]
,
Jinlong Song1 Department of Surgical Oncology (Interventional Therapy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of ChinaCorrespondence[email protected]
,
Zixiang Li4 Department of Interventional Radiology, Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of China
,
Jize Sun5 Department of Interventional Radiology, Qingdao Central Hospital, Qingdao, People’s Republic of China
,
Yili Xu6 Department of Interventional Radiology, 960 Hospital of People’s Liberation Army, Tai’an, People’s Republic of China
,
Zhaomin Zheng7 Department of Interventional Radiology, Qianfoshan Hospital of Shandong Province, Jinan, People’s Republic of China
,
Jingqin Cao8 Department of Interventional Radiology, People’s Hospital of Jining City, Jining, People’s Republic of China
&
Lei Zhang3 Department of Interventional Radiology, Shandong Medical Imaging Research Institute, Jinan, People’s Republic of China
 show all
Pages 9863-9869 | Published online: 19 Nov 2019

References

  • Cheung TT, Kwok PC, Chan S, et al. Hong Kong consensus statements for the management of unresectable hepatocellular carcinoma. Liver Cancer. 2018;7:40–54. doi:10.1159/00048598429662832
  • Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370. doi:10.1007/s12072-017-9799-928620797
  • Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022. doi:10.1002/hep.2419921374666
  • Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234–1246. doi:10.1245/s10434-010-0977-420405328
  • Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–3508. doi:10.1200/JCO.2012.44.564323980077
  • Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395–1403. doi:10.1200/JCO.2005.03.816616505413
  • Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25:5649–5654. doi:10.1200/JCO.2007.12.176418065736
  • Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2009;3:CD007823. doi:10.1002/14651858.CD007823.pub2
  • Gravalos C, Salut A, Garcia-Giron C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012;14:606–612. doi:10.1007/s12094-012-0843-x22855138
  • Liu Y, Wu W, Hong W, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer. Clin Res Hepatol Gastroenterol. 2014;38:219–225. doi:10.1016/j.clinre.2013.11.00624388340
  • Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs. 2010;21:656–661. doi:10.1097/CAD.0b013e328337d46920216061
  • Guo JH, Zhang HY, Gao S, et al. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World J Gastroenterol. 2017;23:1406–1411. doi:10.3748/wjg.v23.i8.140628293087
  • Shao G, Liu R, Ding W, et al. Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases. Anticancer Drugs. 2018;29:1021–1025. doi:10.1097/CAD.000000000000069030134285
  • Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol. 2010;25:439–452. doi:10.1111/j.1440-1746.2009.06207.x20370723
  • Cui W, Fan W, Zhang Q, et al. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin. Oncotarget. 2017;45:79165–79174. doi:10.18632/ontogarget.16298
  • Zhao C, Fan L, Qi F, et al. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Anticancer Drugs. 2016;27:689–694. doi:10.1097/CAD.000000000000037127145327
  • Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343–1350. doi:10.1111/j.1365-2036.2012.05089.x22486716
  • Georgiades C, Geschwind JF, Harrison N, et al. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology. 2012;265:115–123. doi:10.1148/radiol.1211226422891361
  • Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–718. doi:10.1148/radiol.1111028222187634
  • Kim BK, Kim SU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304–1310. doi:10.1016/j.jhep.2015.01.02225637785

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.